Modality
Degrader
MOA
WRNi
Target
TNFα
Pathway
Incretin
HSNSCLCCeliac
Development Pipeline
Preclinical
~Aug 2012
→ ~Nov 2013
Phase 1
~Feb 2014
→ ~May 2015
Phase 2
~Aug 2015
→ ~Nov 2016
Phase 3
~Feb 2017
→ ~May 2018
NDA/BLA
Aug 2018
→ Aug 2027
NDA/BLACurrent
NCT08871942
1,861 pts·HS
2021-10→2026-05·Completed
NCT05121664
1,887 pts·HS
2018-08→2027-08·Active
3,748 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-121mo awayPh3 Readout· HS
2027-08-211.4y awayPh3 Readout· HS
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Active
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2026-05-12 · 1mo away
HS
Ph3 Readout
2027-08-21 · 1.4y away
HS
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08871942 | NDA/BLA | HS | Completed | 1861 | PANSS |
| NCT05121664 | NDA/BLA | HS | Active | 1887 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα |